US 11,717,523 B2
Transient protection of normal cells during chemotherapy
Jay Copeland Strum, Hillsborough, NC (US); John Emerson Bisi, Chapel Hill, NC (US); Patrick Joseph Roberts, Durham, NC (US); and Francis Xavier Tavares, Durham, NC (US)
Assigned to G1 Therapeutics, Inc., Research Triangle Park, NC (US)
Filed by G1 Therapeutics, Inc., Research Triangle Park, NC (US)
Filed on Apr. 5, 2021, as Appl. No. 17/222,873.
Application 17/222,873 is a continuation of application No. 16/112,360, filed on Aug. 24, 2018, granted, now 10,966,984.
Application 16/112,360 is a continuation of application No. 15/342,990, filed on Nov. 3, 2016, granted, now 10,085,992, issued on Oct. 2, 2018.
Application 15/342,990 is a continuation of application No. 14/212,430, filed on Mar. 14, 2014, granted, now 9,487,530, issued on Nov. 8, 2016.
Claims priority of provisional application 61/949,786, filed on Mar. 7, 2014.
Claims priority of provisional application 61/911,354, filed on Dec. 3, 2013.
Claims priority of provisional application 61/861,374, filed on Aug. 1, 2013.
Claims priority of provisional application 61/798,772, filed on Mar. 15, 2013.
Prior Publication US 2021/0299130 A1, Sep. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/527 (2006.01); C07D 487/14 (2006.01); A61K 45/06 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61P 35/04 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 31/555 (2006.01); A61K 31/7048 (2006.01)
CPC A61K 31/527 (2013.01) [A61K 9/0053 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/555 (2013.01); A61K 31/7048 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07D 487/14 (2013.01)] 21 Claims
 
1. A method of reducing chemotherapy-induced myelosuppression in a human receiving chemotherapy for the treatment of small cell lung cancer comprising administering to the human an effective amount of at least one chemotherapeutic agent and an effective amount of a CDK4/6 inhibitor of the structure

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein the CDK4/6 inhibitor is administered 24 hours or less prior to administration of the chemotherapeutic agent.